FDA MedWatch

FDA Drug Safety Newsletter- Summer 2008 Edition Available For Healthcare Professionals And The Medical Community

09/18/2008- The Drug Safety Newsletter is a FDA publication for healthcare professionals and the medical community. The newsletter provides information on the findings of selected postmarketing drug safety reviews from FDA's Center for Drug Evaluation and Research. The newsletter also provides information on important emerging drug safety issues and recently approved new molecular entities. FDA hopes the newsletter will raise awareness of reported adverse events, and stimulate additional adverse event reporting by healthcare professionals. Postmarketing Reviews: Mefloquine Hydrochloride: Reports of Pneumonitis Lenalidomide: Serious Skin Reactions Amiodarone-Simvastatin Interaction: Reports of rhabdomyolysis Icodextrin Portable Blood Glucose Monitor Test Strip Interaction: Reports of iatrogenic, sometimes fatal, hypoglycemia Publication of this newsletter fulfills a commitment FDA made in its January 2007 response to the Institute of Medicine's (IOM) 2006 Report on The Future of Drug Safety - Promoting and Protecting the Health of the Public. Read the entire MedWatch 2008 Safety Summary, including a link to the FDA Drug Safety Newsletter at:

http://www.fda.gov/cder/dsn/2008_summer/toc.htm